Sonic Healthcare Limited (SKHCF) Stock Price & Analysis
Sonic Healthcare Limited (SKHCF) closed at USD 13 on Wednesday, October 21, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13; the Oct 21, 2026 session ranged USD 13–13 on volume of 200 shares. Market capitalization is $6.88B, with a 52-week range of USD 11.67–16.1 (PNK). Source: Nexqual, retrieved October 23, 2026 at 17:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SKHCF.md
Key facts (SKHCF)
- Analysts: None.
- Total return with dividends: 1Y +13.7% vs S&P 500 +14.4%; 5Y -45.6% vs S&P 500 +77.1%.
- Next earnings: 2026-08-20, EPS estimate USD —, revenue estimate $0K.
Analysts (SKHCF)
Consensus None.
Total return (dividends reinvested) (SKHCF)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +13.7% | -45.6% |
| S&P 500 (SPY) | +14.4% | +77.1% |
| Per year | +13.8% | -11.5% |
| Volatility (annualized) | 52.0% | 38.0% |
| Max drawdown | -25.0% (Mar 2026→May 2026) | -57.3% (Dec 2021→May 2026) |
SKHCF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Jun 2027) | — | — | — | $11.11B | — |
| Next fiscal year (ends Jun 2028) | — | — | — | $11.56B | — |
Key Statistics (as of October 23, 2026 at 17:49 UTC)
| Price | USD 13 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 13 |
| Open | USD 13 |
| Day Range | USD 13 – 13 |
| 52-Week Range | USD 11.67 – 16.1 |
| Volume | 200 shares |
| Market Cap | $6.88B |
| Exchange | PNK |
Technical Analysis (SKHCF)
Nexqual's technical model rates SKHCF "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 17:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.66 (neutral) |
| vs SMA50 | Below (USD 13.41) |
| MACD | -0.05 (negative) |
Analyst Ratings (SKHCF)
Wall Street analysts rate SKHCF "None", per Nexqual as of October 23, 2026 at 17:49 UTC.
| Consensus Rating | None |
|---|
Earnings (SKHCF)
| Next Earnings Date | 2026-08-20 |
|---|
Source: Nexqual, October 23, 2026 at 17:49 UTC.
Financials & Fundamentals (SKHCF)
| Total Revenue | $10.87B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.90% |
| Gross Margin | +32.99% |
| Operating Margin | +9.65% |
| Profit Margin | +5.60% |
| ROE | +7.50% |
| Debt / Equity | 0.69 |
| Current Ratio | 0.99 |
| Total Cash | $653.69M |
| Total Debt | $5.84B |
Source: Nexqual, October 23, 2026 at 17:49 UTC.
Financial Health Score (SKHCF)
Nexqual rates Sonic Healthcare Limited's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 17:49 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 10% (last 12 months) |
| Balance Sheet | Mixed — AUD 654M cash vs AUD 5.84B debt |
| Cash Flow | Solid — Operating cash flow AUD 1.41B (TTM) |
| Efficiency | Mixed — ROE 8%, ROA 3.9% |
Ownership (SKHCF)
| Insider Ownership | +7.99% |
|---|---|
| Institutional Ownership | +49.50% |
| Shares Outstanding | 494.24M |
| Float | 459.82M |
Source: Nexqual, October 23, 2026 at 17:49 UTC.
Leadership (SKHCF)
Sonic Healthcare Limited is led by James Pacey Newcombe, MD, CEO & Executive Director, per Nexqual as of October 23, 2026 at 17:49 UTC.
| MD, CEO & Executive Director | James Pacey Newcombe |
|---|---|
| Finance Director, CFO & Executive Director | Christopher David Wilks B.Com., F.A.C.I.D., F.A.I.C.D. |
| Group Chief Operating Officer | Evangelos Kotsopoulos |
Major Backers & Investors (SKHCF)
Notable institutional backers of Sonic Healthcare Limited include John Hancock Investment Trust-Disciplined Value International Fund, Fidelity, TRANSAMERICA FUNDS-Transamerica International Equity, according to Nexqual as of October 23, 2026 at 17:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| John Hancock Investment Trust-Disciplined Value International Fund | 0.92% |
| Fidelity | 0.65% |
| TRANSAMERICA FUNDS-Transamerica International Equity | 0.34% |
| J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Developed Asia Paci | 0.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.31% |
| BlackRock | 1% |
| Dimensional Fund Advisors | 0.44% |
Source: Nexqual, October 23, 2026 at 17:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRAL | GRAIL, Inc. | USD 135.1 | ▲ 6.33% |
| RDNT | RadNet, Inc. | USD 69.87 | ▼ 0.56% |
| SHC | Sotera Health Company | USD 17.97 | ▼ 0.91% |
| QGEN | Qiagen N.V. | USD 50.38 | ▲ 0.31% |
| BLLN | BillionToOne, Inc. | USD 107.98 | ▲ 2.18% |
| ADPT | Adaptive Biotechnologies Corpor | USD 25.48 | ▲ 4.38% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 17:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt